|
|
发表于 24-11-2009 12:00 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 24-11-2009 06:40 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 24-11-2009 09:33 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 24-11-2009 09:52 PM
|
显示全部楼层
CVM
Pre-Market Last: $ 1.34
Pre-Market High: $ 1.34
Pre-Market Low: $ 1.30
Pre-Market Volume: 7,584 |
|
|
|
|
|
|
|
|
|
|
|
发表于 25-11-2009 06:34 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 25-11-2009 08:18 PM
|
显示全部楼层
http://vfcsstockhouse.blogspot.com/2009/11/briefs-cvm.html
Tuesday, November 24, 2009
Briefs: CVM
CVM: Shares of Cel Sci Corp. continued to hover right around the $1.30 mark even after TheStreet.com's infamous biotech blogger thrust his most recent blogging salvo at Cel Sci in an attempt to keep his ongoing vendetta against the company alive - for reasons that are still yet to be known.
We can only speculate as to why Feuerstein spends so much time attempting to attack Cel Sci, but in my opinion, the reasons range from hooking up his friends who are either short the stock and looking to cover and/or hooking up his boys that may want in on a good thing. Additionally, any article regarding Cel Sci will undoubtedly draw many 'hits' to his blog - and those hits are very important for advertising revenue when your living is blogging; hence the need to both stretch out one article over multiple pages (one reader then accounts for multiple hits) and the need to make sure that a Cel Sci article is somehow attached to another published article that has nothing to do with Cel Sci. Pretty slick, I guess the past few days will make up for the lost 'clicks' due to the Thanksgiving holiday.
As for what's important - Cel Sci - news regarding the validation of the Baltimore area manufacturing facility has to be imminent, when considering the previous time frames announced by the company; and once the facility is 'good to go', I would expect an announcement stating that the long-awaited and much-anticipated Multikine Phase III trial is finally set to begin.
Any updates from the Johns Hopkins LEAPS/H1N1 trial would be an added bonus, in my opinion.
The holiday season is ripe, and regardless of the amount of time that the grinch is spending trying to ruin the holiday cheer for shareholders of Cel Sci, it looks like the residents of Whoville are starting to ignore the incessant and highly predictable griping of the grinch.
In my opinion, a few shares of CVM as stocking stuffers for this holiday season could pay off very well down the road - based on the potential of Multikine and LEAPS.
As always, each investor should do his or her own DD and invest accordingly.
Disclosure: VFC is long CVM. |
|
|
|
|
|
|
|
|
|
|
|
发表于 25-11-2009 08:26 PM
|
显示全部楼层
http://finance.yahoo.com/news/Hu ... 8.html?x=0&.v=1
Human Genome Sciences Submits Biologics License Application to FDA for ZALBIN
Press Release
Source: Human Genome Sciences, Inc.
On 7:01 am EST, Wednesday November 25, 2009
ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI - News) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.
The Phase 3 studies, known as ACHIEVE 1 and ACHIEVE 2/3, evaluated albinterferon alfa-2b vs. peginterferon alfa-2a, in combination with ribavirin, for use in the treatment of interferon-naïve patients with chronic hepatitis C. In both studies, albinterferon alfa-2b, with half the injections, achieved sustained virologic response comparable to that achieved by peginterferon alfa-2a. The rates of serious and/or severe adverse events were also comparable in these studies. ACHIEVE 1 was conducted in patients infected with genotype 1 virus, and ACHIEVE 2/3 was conducted in patients with genotypes 2 or 3 virus. The two studies treated a total of 2255 patients.
“We look forward to continuing to work closely with Novartis to advance albinterferon alfa-2b to the market under the brand name ZALBIN in the United States,” said H. Thomas Watkins, President and Chief Executive Officer, HGS. “Assuming licensure by the FDA and other regulatory agencies, HGS believes ZALBIN could become an important treatment for chronic hepatitis C. Novartis targets submission of marketing authorization applications under the brand name JOULFERON® in the rest of the world later this quarter, beginning with Europe.” |
|
|
|
|
|
|
|
|
|
|
|
发表于 25-11-2009 08:32 PM
|
显示全部楼层
恭喜麥麥。
HGSI 價錢越來越高了。。  |
|
|
|
|
|
|
|
|
|
|
|
发表于 25-11-2009 09:29 PM
|
显示全部楼层
回复 668# 葉芬 的帖子
|
槌心肝的了，那时我看到这个股是才 <1Usd,，我还记得没选择它而买了OSCI, LJPC，这两个都差不多都去荷兰村了！ |
|
|
|
|
|
|
|
|
|
|
|
发表于 25-11-2009 09:48 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 25-11-2009 10:29 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 25-11-2009 10:45 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 25-11-2009 11:10 PM
|
显示全部楼层
原帖由 miku 于 25-11-2009 10:45 PM 发表 
CVM 等好久。。。
她的好消息要出來了。。。
估計是12月第一星期。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 25-11-2009 11:36 PM
|
显示全部楼层
|
是吗，那就如果今天卖掉snv的话全买cvm。。呵呵 |
|
|
|
|
|
|
|
|
|
|
|
发表于 26-11-2009 02:24 AM
|
显示全部楼层
Buy 4000 shares RPRX @ 0.694 on 25/11/09
Sell 4000 shares RPRX @ 0.850 on 26/11/09
小赚USD 500 多 after commission
祝大家好運!!! |
|
|
|
|
|
|
|
|
|
|
|
发表于 26-11-2009 09:34 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 26-11-2009 09:41 AM
|
显示全部楼层
原帖由 m.i.k.e 于 25-11-2009 10:29 PM 发表 
今晚注意 sinovac , incy
我有注意。。不過今天BuyLimit不大夠，要留子彈給CVM及MPEL。。
所以只齋看。。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 26-11-2009 09:50 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 26-11-2009 10:06 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 27-11-2009 09:33 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
！
1326 
92
